Loading…
Loading…
McKesson operates within a US pharma distribution oligopoly, generating $5B+ in FCF and aggressively repurchasing shares. The oncology segment is driving growth, with a 31% YoY revenue increase and strategic acquisitions reinforcing the shift toward higher-margin businesses. Despite negative shareholder equity from buybacks and opioid liabilities, MCK maintains strong liquidity, low leverage, and disciplined capital returns.
Barlow Wealth Partners LLC lifted its position in shares of McKesson Corporation (NYSE: MCK) by 96.4% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 33,820 shares of the company's stock after purchasing an additional 16,596 shares during the
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
A prolific hacking group has taken credit for last week's cyberattack against U.S. pharmaceutical distribution giant McKesson, leading to the latest spill of highly sensitive health data by an American healthcare company in recent months.
Beacon Pointe Advisors LLC purchased a new position in shares of McKesson Corporation (NYSE: MCK) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 20,343 shares of the company's stock, valued at approximately $15,371,000. A number of other hedge funds and
MCK's $2.25B Precision Medicine Group deal aims to expand clinical research and commercialization services in oncology and multispecialty care.
MCK's specialty distribution, oncology and technology businesses are fueling growth, while drug-pricing pressure and policy shifts pose risks.